Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | QPCT | Q16769 | 1/20 | 0.31 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.30 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7853098 | 0.98 | KDM4E (0.33) | KDM4EALDH1A1CYP1A2CYP2D6HPGD | |
| SCHEMBL7659720 | 0.88 | CAMK2D (0.36) | KDM4EALDH1A1CYP1A2CYP2D6HPGD | |
| SCHEMBL7653829 | 0.87 | CNR2 (0.36) | GSK3BQPCT | |
| SCHEMBL7662842 | 0.87 | PDE4B (0.40) | TDP1GSK3BQPCT | |
| SCHEMBL7666393 | 0.86 | CAMK2D (0.36) | GSK3BQPCT | |
| SCHEMBL7665495 | 0.85 | CAMK2D (0.41) | GSK3B | |
| SCHEMBL7655899 | 0.85 | TP53 (0.39) | KDM4EALDH1A1HPGD | |
| SCHEMBL7662560 | 0.85 | PDE4B (0.40) | GSK3BQPCT | |
| SCHEMBL8516957 | 0.84 | CAMK2D (0.37) | KDM4EALDH1A1CYP1A2CYP2D6HPGD | |
| SCHEMBL7664149 | 0.84 | CAMK2D (0.41) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458792-B1 | MEDICAMENT FOR THE TREATMENT OF INFLAMMATORY, IMMUNOLOGICAL, BRONCHOPULMONARY, CARDIOVASCULAR, ONCOLOGICAL OR CNS-DEGENERATIVE DISORDERS. | ASTRAZENECA AB (SE) | 2002-10-01 | — | — | US | disclosed |
| EP-1071683-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999046264-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 1999-09-16 | — | — | WO | disclosed |